Edition:
India

Horizon Therapeutics PLC (HZNP.OQ)

HZNP.OQ on NASDAQ Stock Exchange Global Select Market

24.63USD
1:30am IST
Change (% chg)

$0.34 (+1.40%)
Prev Close
$24.29
Open
$24.37
Day's High
$24.78
Day's Low
$24.10
Volume
600,180
Avg. Vol
635,925
52-wk High
$29.44
52-wk Low
$16.57

About

Horizon Therapeutics PLC, formerly Horizon Pharma Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $4,490.83
Shares Outstanding(Mil.): 184.88
Dividend: --
Yield (%): --

Financials

  HZNP.OQ Industry Sector
P/E (TTM): 311.89 30.18 34.10
EPS (TTM): 0.08 -- --
ROI: 0.41 12.97 12.64
ROE: 1.09 14.15 17.18

Recordati to seek Canadian approval for kidney disease drug

TORONTO Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.

16 Apr 2019

Recordati to seek Canadian approval for kidney disease drug

TORONTO, April 16 Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.

16 Apr 2019

Earnings vs. Estimates